FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054266161> ?p ?o ?g. }

• W2054266161 endingPage "211" @default.
• W2054266161 startingPage "203" @default.
• W2054266161 abstract "Safety of Avastin in Lung (MO19390) was an international, open-label, single-arm study, which assessed the safety and efficacy of first-line bevacizumab (Avastin®) in combination with standard chemotherapy in patients (n = 2212) with advanced or recurrent non-small cell lung cancer (NSCLC). A preplanned subgroup analysis was performed to examine these outcomes in elderly patients older than 65 years.Eligible patients with nonsquamous NSCLC received up to six cycles of bevacizumab (7.5 or 15 mg/kg) plus any standard of care chemotherapy. Patients who did not experience disease progression after induction therapy continued bevacizumab therapy until disease progression or unacceptable toxicity. The primary end point was safety; secondary end points included time to disease progression (TTP) and overall survival (OS).Data were evaluated for 623 patients older than 65 years (mean age 70.6). The majority were Whites (86.2%) with stage IV disease (79.7%) and had adenocarcinoma (83.5%). The incidence of adverse events (AEs) of special interest was similar for elderly and younger patients (any grade bleeding 38.2% versus 38.3%; any grade hypertension 33.1% versus 30.6%; any grade proteinuria 33.4% versus 29.3%). Most AEs were grade less than or equal to 2. Serious AEs were reported in 45.3 and 34.7% of elderly and younger patients, respectively. Median OS was similar in elderly and younger patients (14.6 months in both age groups), as were TTP (8.2 versus 7.6 months), response rate (49.3% versus 52.4%), and disease control rate (89.3% versus 88.4%). Similar results were seen in a post hoc comparison of the older than 70 years and 70 years or younger subgroups: TTP was 8.6 months versus 7.7 months, respectively; OS was 14.6 months in both subgroups; response rate was 49% and 52%, respectively; incidence of AEs of special interest was comparable.Patients older than 65 years with nonsquamous NSCLC derive a similar clinical benefit from first-line bevacizumab-based therapy as their younger counterparts and do not experience increased toxicity." @default.
• W2054266161 created "2016-06-24" @default.
• W2054266161 creator A5008403882 @default.
• W2054266161 creator A5017960622 @default.
• W2054266161 creator A5023043755 @default.
• W2054266161 creator A5029761367 @default.
• W2054266161 creator A5046728958 @default.
• W2054266161 creator A5051864484 @default.
• W2054266161 creator A5052978985 @default.
• W2054266161 creator A5072563857 @default.
• W2054266161 creator A5088331751 @default.
• W2054266161 date "2012-01-01" @default.
• W2054266161 modified "2023-10-16" @default.
• W2054266161 title "Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)" @default.
• W2054266161 cites W1496563114 @default.
• W2054266161 cites W1935885922 @default.
• W2054266161 cites W1966162777 @default.
• W2054266161 cites W1989420121 @default.
• W2054266161 cites W2016156617 @default.
• W2054266161 cites W2037139573 @default.
• W2054266161 cites W2038798176 @default.
• W2054266161 cites W2067790939 @default.
• W2054266161 cites W2097124809 @default.
• W2054266161 cites W2101751898 @default.
• W2054266161 cites W2115330744 @default.
• W2054266161 cites W2120757327 @default.
• W2054266161 cites W2126310082 @default.
• W2054266161 cites W2126856198 @default.
• W2054266161 cites W2127305631 @default.
• W2054266161 cites W2127405377 @default.
• W2054266161 cites W2137009016 @default.
• W2054266161 cites W2140872365 @default.
• W2054266161 cites W2144660856 @default.
• W2054266161 cites W2145653040 @default.
• W2054266161 cites W2145835533 @default.
• W2054266161 cites W2154581953 @default.
• W2054266161 cites W2160131381 @default.
• W2054266161 cites W2162328883 @default.
• W2054266161 cites W2163787988 @default.
• W2054266161 cites W2165048128 @default.
• W2054266161 cites W2166399931 @default.
• W2054266161 cites W2241535667 @default.
• W2054266161 cites W2331849216 @default.
• W2054266161 cites W4236421510 @default.
• W2054266161 cites W4239714259 @default.
• W2054266161 cites W6288358 @default.
• W2054266161 doi "https://doi.org/10.1097/jto.0b013e3182370e02" @default.
• W2054266161 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22173662" @default.
• W2054266161 hasPublicationYear "2012" @default.
• W2054266161 type Work @default.
• W2054266161 sameAs 2054266161 @default.
• W2054266161 citedByCount "64" @default.
• W2054266161 countsByYear W20542661612012 @default.
• W2054266161 countsByYear W20542661612013 @default.
• W2054266161 countsByYear W20542661612014 @default.
• W2054266161 countsByYear W20542661612015 @default.
• W2054266161 countsByYear W20542661612016 @default.
• W2054266161 countsByYear W20542661612017 @default.
• W2054266161 countsByYear W20542661612018 @default.
• W2054266161 countsByYear W20542661612019 @default.
• W2054266161 countsByYear W20542661612020 @default.
• W2054266161 countsByYear W20542661612021 @default.
• W2054266161 countsByYear W20542661612022 @default.
• W2054266161 countsByYear W20542661612023 @default.
• W2054266161 crossrefType "journal-article" @default.
• W2054266161 hasAuthorship W2054266161A5008403882 @default.
• W2054266161 hasAuthorship W2054266161A5017960622 @default.
• W2054266161 hasAuthorship W2054266161A5023043755 @default.
• W2054266161 hasAuthorship W2054266161A5029761367 @default.
• W2054266161 hasAuthorship W2054266161A5046728958 @default.
• W2054266161 hasAuthorship W2054266161A5051864484 @default.
• W2054266161 hasAuthorship W2054266161A5052978985 @default.
• W2054266161 hasAuthorship W2054266161A5072563857 @default.
• W2054266161 hasAuthorship W2054266161A5088331751 @default.
• W2054266161 hasBestOaLocation W20542661611 @default.
• W2054266161 hasConcept C126322002 @default.
• W2054266161 hasConcept C141071460 @default.
• W2054266161 hasConcept C143998085 @default.
• W2054266161 hasConcept C168563851 @default.
• W2054266161 hasConcept C197934379 @default.
• W2054266161 hasConcept C203092338 @default.
• W2054266161 hasConcept C2776256026 @default.
• W2054266161 hasConcept C2776694085 @default.
• W2054266161 hasConcept C2777802072 @default.
• W2054266161 hasConcept C2779561371 @default.
• W2054266161 hasConcept C2780091579 @default.
• W2054266161 hasConcept C71924100 @default.
• W2054266161 hasConceptScore W2054266161C126322002 @default.
• W2054266161 hasConceptScore W2054266161C141071460 @default.
• W2054266161 hasConceptScore W2054266161C143998085 @default.
• W2054266161 hasConceptScore W2054266161C168563851 @default.
• W2054266161 hasConceptScore W2054266161C197934379 @default.
• W2054266161 hasConceptScore W2054266161C203092338 @default.
• W2054266161 hasConceptScore W2054266161C2776256026 @default.
• W2054266161 hasConceptScore W2054266161C2776694085 @default.
• W2054266161 hasConceptScore W2054266161C2777802072 @default.
• W2054266161 hasConceptScore W2054266161C2779561371 @default.
• W2054266161 hasConceptScore W2054266161C2780091579 @default.

• next